MX2021000895A - Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos. - Google Patents

Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.

Info

Publication number
MX2021000895A
MX2021000895A MX2021000895A MX2021000895A MX2021000895A MX 2021000895 A MX2021000895 A MX 2021000895A MX 2021000895 A MX2021000895 A MX 2021000895A MX 2021000895 A MX2021000895 A MX 2021000895A MX 2021000895 A MX2021000895 A MX 2021000895A
Authority
MX
Mexico
Prior art keywords
cdk inhibitors
cdk6
cdk4
compositions
methods
Prior art date
Application number
MX2021000895A
Other languages
English (en)
Inventor
Michael D Bartberger
Dylan Conklin
Dennis Slamon
Brendan M O''boyle
Justin A Hilf
Scott C Virgil
Alexander W Sun
Brian M Stoltz
Martina Mcdermott
Neil A O''brien
Michael J Palazzolo
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of MX2021000895A publication Critical patent/MX2021000895A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

La presente descripción proporciona compuestos y composiciones que son inhibidores de CDK selectivos para CDK4 y/o CDK6 y métodos de uso de los mismos.
MX2021000895A 2018-07-27 2019-07-26 Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos. MX2021000895A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862711192P 2018-07-27 2018-07-27
PCT/US2019/043754 WO2020023917A1 (en) 2018-07-27 2019-07-26 Cdk inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2021000895A true MX2021000895A (es) 2021-08-24

Family

ID=69181984

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000895A MX2021000895A (es) 2018-07-27 2019-07-26 Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.

Country Status (12)

Country Link
US (1) US20220106325A1 (es)
EP (1) EP3830082A4 (es)
JP (1) JP2021531349A (es)
KR (1) KR20210062626A (es)
CN (1) CN112703186A (es)
AU (2) AU2019310595B2 (es)
BR (1) BR112021001499A2 (es)
CA (1) CA3107750A1 (es)
IL (1) IL280408A (es)
MX (1) MX2021000895A (es)
SG (1) SG11202100429TA (es)
WO (1) WO2020023917A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP2113246B1 (en) 2003-08-07 2016-06-22 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
WO2016015604A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN107266421B (zh) * 2016-04-08 2020-12-04 正大天晴药业集团股份有限公司 取代的苯并咪唑类衍生物
WO2018045956A1 (zh) * 2016-09-07 2018-03-15 江苏豪森药业集团有限公司 苯并咪唑类化合物激酶抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
AU2019310595A1 (en) 2021-02-04
IL280408A (en) 2021-03-25
EP3830082A1 (en) 2021-06-09
WO2020023917A1 (en) 2020-01-30
US20220106325A1 (en) 2022-04-07
CN112703186A (zh) 2021-04-23
EP3830082A4 (en) 2022-05-11
BR112021001499A2 (pt) 2021-04-27
KR20210062626A (ko) 2021-05-31
SG11202100429TA (en) 2021-02-25
AU2022291606A1 (en) 2023-02-02
AU2019310595B2 (en) 2022-11-24
JP2021531349A (ja) 2021-11-18
CA3107750A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12018501656A1 (en) Methods for using fxr agonists
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
BR112018071184A2 (pt) inibidores do receptor de activina tipo quinase
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
EA201691916A1 (ru) Биарильные ингибиторы киназы
MX2022013114A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.